Promomed's profit for 2024 under IFRS decreased by 3% to 2.87 billion rubles from 2.97 billion rubles a year earlier. This is stated in the company's report. Net profit, adjusted for one—time expenses, increased by 22% to 4.025 billion rubles from 3.311 billion rubles, revenue — by 35% to 21.449 billion rubles from 15.842 billion rubles, EBITDA - by 31% to 8.229 billion rubles from 6.281 billion rubles.
The total remuneration to the group's key management personnel represents short-term payments and expenses under the long-term incentive program and is included in commercial, general and administrative expenses in the consolidated statement of profit or loss and other comprehensive income for the year ended December 31, 2024 in the amount of RUB 308.225 million. (for the year ended December 31, 2023 — 113.386 million rubles). The total number of key management personnel of the group as of December 31, 2024 was 7 (as of December 31, 2023 — 7).
In 2024, the group recorded total expenses for operations related to share-based payments in the amount of 82.725 million rubles.
During 2024 and 2023, the group did not declare or pay dividends.
In 2024, the group made other capital distributions in favor of the owners in the amount of RUB 13.753 million, taking into account the restoration of the previously recognized estimated liability. In 2023, the group made other capital distributions in favor of the owners in the amount of RUB 292.133 million.
The financial statements say that on December 31, 2024, PROMOMED DM LLC became 77.94% owner of Promomed Holdings LLC, Miracle Farm LLC — 70% owner of PROMOMED — Animal Health LLC.
Thus, on March 15, 2024, the group completed the acquisition of a 77.94% stake in Promomed Holdings LLC. At the time of the acquisition, Promomed Holdings LLC owned 100% of the shares of Promomed Holdings (Cyprus) Limited. The purpose of the transaction is to buy out 6% of shares of PJSC PROMOMED owned by Promomed Holdings (Cyprus) Limited. The value of the transaction was 928.25 million rubles. The agreement provides for a repayment schedule with a delay of up to one calendar year. This transaction is not a business combination. On March 28, 2025, the Group fully repaid the debt under the deal to acquire a 77.94% stake in Promomed Holdings LLC.
In March 2023, the group invested in the capital of ARTSELLENS LLC, whose main activity is the production of medicines and materials used for medical purposes. The main region of activity is the Russian Federation. As of December 31, 2024 and December 31, 2023, the group owns 49% of the capital of this organization. The Group's management evaluates this investment as an investment in an associate accounted for using the equity method.
On March 31, 2025, the reorganization procedure began with the participation of the group's companies, as a result of which NPC Antibiotics LLC will be merged into PROMOMED RUS LLC. The Group plans to complete the reorganization in 2025.
Non-controlling interests are represented as follows: 10% in the authorized capital of Promark LLC as at December 31, 2024 and December 31, 2023, respectively; 49% in the authorized capital of Berakhim LLC as at December 31, 2024 and December 31, 2023, respectively; 22.06% in the authorized capital of Promomed Holdings LLC as at December 31, 2024; 30% in the authorized capital of PROMOMED — Animal Health LLC as of December 31, 2024.
Promomed is a biopharmaceutical company. The main activities of the group are the production, development and wholesale of pharmaceutical products. The Group's production facilities are located in the cities of Saransk and Obninsk, Russian Federation.
Promomed Group was initially established by several individuals as a group of companies operating in the pharmaceutical market of the Russian Federation.
PJSC Promomed (the parent company of the group) was established on July 16, 2021.
As of December 31, 2024 and December 31, 2023, the ultimate controlling owner of the group was Peter Bely. As of December 31, 2024, he owns 87.67% of the authorized capital. A 5.65% stake belongs to Promomed Holdings LLC, while 6.68% is held nominally.
According to RAS, in 2024, the loss of PJSC Promomed amounted to 38.552 million rubles against a loss of 116.492 million rubles. 52.867 million rubles were spent on employee compensation against 17.494 million rubles (cash flows from current operations). The average number of employees in 2024 was 3, in 2023 — 0. Revenues from subsidiaries and affiliated companies increased to 93.17 million rubles from 46.83 million rubles.
